Bioequivalence study of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and efavirenz

Trial Profile

Bioequivalence study of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and efavirenz

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Efavirenz; Emtricitabine; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 27 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top